Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs.

摘要: Glioblastoma is the most aggressive and lethal primary brain malignancy, with an average patient survival from diagnosis of 14 months. also usually progresses as a more invasive phenotype after initial treatment. A major step forward in our understanding nature glioblastoma was achieved large-scale expression analysis. However, due to genomic complexity heterogeneity, transcriptomics alone not enough define "fingerprint", so epigenetic mechanisms are being examined, including noncoding genome. On basis their tissue specificity, long RNAs (lncRNAs) explored new diagnostic therapeutic targets. In addition, growing evidence indicates that lncRNAs have various roles resistance therapies (e.g., MALAT1, H19) progression CRNDE, HOTAIRM1, ASLNC22381, ASLNC20819). Investigations focused on prognostic value lncRNAs, well definition molecular signatures glioma, provide precise tumor classification. This review discusses potential hold for development novel and, hopefully, targets can contribute prolonged improved quality life patients glioblastoma.